Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.

In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM who have exhausted treatment with lenalidomide and bortezomib. The optimal starting dose of pomalidomide is 4 mg given on days 1-21 of each 28-day cycle, while dexamethasone is administered at a dose of 40 mg weekly (reduced to 20 mg for patients aged >75 years). The treatment should continue until evidence of disease progression or unacceptable toxicity. Dose-modification schemes have been established for patients who develop neutropenia, thrombocytopenia and other grade 3-4 adverse events during pomalidomide therapy. Guidance on the prevention and management of infections and venous thromboembolism are provided, based on the available clinical evidence and the experience of panel members. The use of pomalidomide in special populations, such as patients with advanced age, renal impairment or unfavourable cytogenetic features, is also discussed.Leukemia accepted article preview online, 5 February 2014; doi:10.1038/leu.2014.60.

Leleu, X (author)
Palumbo, A (author)
Moreau, P (author)
Delforge, M (author)
Cavo, M (author)
Ludwig, H (author)
Morgan, G J (author)
Davies, F E (author)
Sonneveld, P (author)
Schey, S A (author)
Zweegman, S (author)
Hansson, MarkusLund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine(Swepub:lu)hema-mha (author)
Weisel, K (author)
Mateos, M V (author)
Facon, T (author)
San Miguel, J F (author)
Avdelningen för hematologi och transfusionsmedicinInstitutionen för laboratoriemedicin (creator_code:org_t)

In:Leukemia: Springer Science and Business Media LLC28:8, s. 1573-15851476-55510887-6924

By the author/editor: Dimopoulos, M A; Leleu, X; Palumbo, A; Moreau, P; Delforge, M; Cavo, M; show more...; Ludwig, H; Morgan, G J; Davies, F E; Sonneveld, P; Schey, S A; Zweegman, S; Hansson, Markus; Weisel, K; Mateos, M V; Facon, T; San Miguel, J F; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.